{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T13:22:33Z","timestamp":1648732953419},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2009,10,17]],"date-time":"2009-10-17T00:00:00Z","timestamp":1255737600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z. Rheumatol."],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1007\/s00393-009-0489-4","type":"journal-article","created":{"date-parts":[[2009,10,16]],"date-time":"2009-10-16T19:27:22Z","timestamp":1255721242000},"page":"733-739","source":"Crossref","is-referenced-by-count":4,"title":["Kristallinduzierte Inflammasomaktivierung: Gicht und Pseudogicht"],"prefix":"10.1007","volume":"68","author":[{"given":"M.","family":"Winzer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.-K.","family":"Tausche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Aringer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,10,17]]},"reference":[{"key":"489_CR1","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","volume":"440","author":"Martinon","year":"2006","unstructured":"Martinon F, Petrilli V, Mayor A et al (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440:237\u2013241","journal-title":"Nature"},{"key":"489_CR2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.coi.2008.01.003","volume":"20","author":"Ye","year":"2008","unstructured":"Ye Z, Ting JP (2008) NLR, the nucleotide-binding domain leucine-rich repeat containing gene family. Curr Opin Immunol 20:3\u20139","journal-title":"Curr Opin Immunol"},{"key":"489_CR3","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.4049\/jimmunol.177.6.3507","volume":"177","author":"Franchi","year":"2006","unstructured":"Franchi L, McDonald C, Kanneganti TD et al (2006) Nucleotide-binding oligomerization domain-like receptors: intracellular pattern recognition molecules for pathogen detection and host defense. J Immunol 177:3507\u20133513","journal-title":"J Immunol"},{"key":"489_CR4","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1600-065X.2008.00624.x","volume":"223","author":"Arend","year":"2008","unstructured":"Arend WP, Palmer G, Gabay C (2008) IL-1, IL-18 and IL-33 families of cytokines. Immunol Rev 223:20\u201338","journal-title":"Immunol Rev"},{"key":"489_CR5","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/sj.cdd.4402038","volume":"14","author":"Martinon","year":"2007","unstructured":"Martinon F, Tschopp J (2007) Inflammatory caspases and inflammasomes: master switches of inflammation. Cell Death Differ 14:10\u201322","journal-title":"Cell Death Differ"},{"key":"489_CR6","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/nature01991","volume":"425","author":"Shi","year":"2003","unstructured":"Shi Y, Evans JE, Rock KL (2003) Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425:516\u2013521","journal-title":"Nature"},{"key":"489_CR7","doi-asserted-by":"crossref","first-page":"9035","DOI":"10.1073\/pnas.0803933105","volume":"105","author":"Cassel","year":"2008","unstructured":"Cassel SL, Eisenbarth SC, Iyer SS et al (2008) The Nalp3 inflammasome is essential for the development of silicosis. Proc Natl Acad Sci USA 105:9035\u20139040","journal-title":"Proc Natl Acad Sci USA"},{"key":"489_CR8","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/nature06939","volume":"453","author":"Eisenbarth","year":"2008","unstructured":"Eisenbarth SC, Colegio OR, O\u2019Connor W et al (2008) Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453:1122\u20131126","journal-title":"Nature"},{"key":"489_CR9","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/ni.1636","volume":"9","author":"Halle","year":"2008","unstructured":"Halle A, Hornung V, Petzold GC et al (2008) The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol 9:857\u2013865","journal-title":"Nat Immunol"},{"key":"489_CR10","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1136\/ard.45.10.858","volume":"45","author":"Burt","year":"1986","unstructured":"Burt HM, Dutt YC (1986) Growth of monosodium urate monohydrate crystals: effect of cartilage and synovial fluid components on in vitro growth rates. Ann Rheum Dis 45:858\u2013864","journal-title":"Ann Rheum Dis"},{"key":"489_CR11","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1136\/ard.50.12.939","volume":"50","author":"McGill","year":"1991","unstructured":"McGill NW, Swan A, Dieppe PA (1991) Survival of calcium pyrophosphate crystals in stored synovial fluids. Ann Rheum Dis 50:939\u2013941","journal-title":"Ann Rheum Dis"},{"key":"489_CR12","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/art.24185","volume":"60","author":"Martin","year":"2009","unstructured":"Martin WJ, Walton M, Harper J (2009) Resident macrophages initiating and driving inflammation in a monosodium urate monohydrate crystal-induced murine peritoneal model of acute gout. Arthritis Rheum 60:281\u2013289","journal-title":"Arthritis Rheum"},{"key":"489_CR13","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1002\/art.10326","volume":"46","author":"Schiltz","year":"2002","unstructured":"Schiltz C, Liote F, Prudhommeaux F et al (2002) Monosodium urate monohydrate crystal-induced inflammation in vivo: quantitative histomorphometric analysis of cellular events. Arthritis Rheum 46:1643\u20131650","journal-title":"Arthritis Rheum"},{"key":"489_CR14","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.3899\/jrheum.080938","volume":"36","author":"Schlesinger","year":"2009","unstructured":"Schlesinger N, Norquist JM, Watson DJ (2009) Serum urate during acute gout. J Rheumatol 36:1287\u20131289","journal-title":"J Rheumatol"},{"key":"489_CR15","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1136\/ard.2006.055251","volume":"65","author":"Zhang","year":"2006","unstructured":"Zhang W, Doherty M, Pascual E et al (2006) EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 65:1301\u20131311","journal-title":"Ann Rheum Dis"},{"key":"489_CR16","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1136\/ard.2003.015743","volume":"63","author":"Tausche","year":"2004","unstructured":"Tausche AK, Richter K, Grassler A et al (2004) Severe gouty arthritis refractory to anti-inflammatory drugs: treatment with anti-tumour necrosis factor alpha as a new therapeutic option. Ann Rheum Dis 63:1351\u20131352","journal-title":"Ann Rheum Dis"},{"key":"489_CR17","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s00296-005-0617-7","volume":"26","author":"Fiehn","year":"2006","unstructured":"Fiehn C, Zeier M (2006) Successful treatment of chronic tophaceous gout with infliximab (Remicade). Rheumatol Int 26:274\u2013276","journal-title":"Rheumatol Int"},{"key":"489_CR18","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1136\/ard.2009.109355","volume":"68","author":"Torres","year":"2009","unstructured":"Torres R, Macdonald L, Croll SD et al (2009) Hyperalgesia, synovitis and multiple biomarkers of inflammation are suppressed by IL-1 inhibition in a novel animal model of gouty arthritis. Ann Rheum Dis 68: 1517-1519","journal-title":"Ann Rheum Dis"},{"key":"489_CR19","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/ar2143","volume":"9","author":"So","year":"2007","unstructured":"So A, De Smedt T, Revaz S, Tschopp J (2007) A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 9:28","journal-title":"Arthritis Res Ther"},{"key":"489_CR20","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1093\/hmg\/ddp164","volume":"18","author":"Ceballos-Picot","year":"2009","unstructured":"Ceballos-Picot I, Mockel L, Potier MC et al (2009) Hypoxanthine-guanine phosphoribosyl transferase regulates early developmental programming of dopamine neurons: implications for Lesch-Nyhan disease pathogenesis. Hum Mol Genet 18:2317\u20132327","journal-title":"Hum Mol Genet"},{"key":"489_CR21","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(08)61344-6","volume":"372","author":"Aringer","year":"2008","unstructured":"Aringer M, Graessler J (2008) Understanding deficient elimination of uric acid. Lancet 372:1929\u20131930","journal-title":"Lancet"},{"key":"489_CR22","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nature742","volume":"417","author":"Enomoto","year":"2002","unstructured":"Enomoto A, Kimura H, Chairoungdua A et al (2002) Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 417:447\u2013452","journal-title":"Nature"},{"key":"489_CR23","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/art.21499","volume":"54","author":"Graessler","year":"2006","unstructured":"Graessler J, Graessler A, Unger S et al (2006) Association of the human urate transporter 1 with reduced renal uric acid excretion and hyperuricemia in a German Caucasian population. Arthritis Rheum 54:292\u2013300","journal-title":"Arthritis Rheum"},{"key":"489_CR24","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/ng.107","volume":"40","author":"Doring","year":"2008","unstructured":"Doring A, Gieger C, Mehta D et al (2008) SLC2A9 influences uric acid concentrations with pronounced sex-specific effects. Nat Genet 40:430\u2013436","journal-title":"Nat Genet"},{"key":"489_CR25","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/ng.106","volume":"40","author":"Vitart","year":"2008","unstructured":"Vitart V, Rudan I, Hayward C et al (2008) SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet 40:437\u2013442","journal-title":"Nat Genet"},{"key":"489_CR26","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ajhg.2007.11.001","volume":"82","author":"Wallace","year":"2008","unstructured":"Wallace C, Newhouse SJ, Braund P et al (2008) Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia. Am J Hum Genet 82:139\u2013149","journal-title":"Am J Hum Genet"},{"key":"489_CR27","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/S0140-6736(08)61343-4","volume":"372","author":"Dehghan","year":"2008","unstructured":"Dehghan A, Kottgen A, Yang Q et al (2008) Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet 372:1953\u20131961","journal-title":"Lancet"},{"key":"489_CR28","first-page":"1306","volume":"28","author":"Moriwaki","year":"2001","unstructured":"Moriwaki Y, Yamamoto T, Takahashi S et al (2001) Spot urine uric acid to creatinine ratio used in the estimation of uric acid excretion in primary gout. J Rheumatol 28:1306\u20131310","journal-title":"J Rheumatol"},{"key":"489_CR29","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","volume":"59","author":"Schumacher","year":"2008","unstructured":"Schumacher HR Jr, Becker MA, Wortmann RL et al (2008) Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 59:1540\u20131548","journal-title":"Arthritis Rheum"},{"key":"489_CR30","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.3899\/jrheum.080814","volume":"36","author":"Becker","year":"2009","unstructured":"Becker MA, Schumacher HR, MacDonald PA et al (2009) Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol 36:1273\u20131282","journal-title":"J Rheumatol"},{"key":"489_CR31","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/ar2659","volume":"11","author":"Harrold","year":"2009","unstructured":"Harrold LR, Andrade SE, Briesacher BA et al (2009) Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res Ther 11:46","journal-title":"Arthritis Res Ther"},{"key":"489_CR32","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1136\/bmj.332.7553.1315","volume":"332","author":"Underwood","year":"2006","unstructured":"Underwood M (2006) Diagnosis and management of gout. BMJ 332:1315\u20131319","journal-title":"BMJ"},{"key":"489_CR33","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/ard.2007.076232","volume":"67","author":"Annemans","year":"2008","unstructured":"Annemans L, Spaepen E, Gaskin M et al (2008) Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000\u20132005. Ann Rheum Dis 67:960\u2013966","journal-title":"Ann Rheum Dis"},{"key":"489_CR34","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S1047-2797(97)00204-4","volume":"8","author":"Rathmann","year":"1998","unstructured":"Rathmann W, Funkhouser E, Dyer AR, Roseman JM (1998) Relations of hyperuricemia with the various components of the insulin resistance syndrome in young black and white adults: the CARDIA study. Coronary Artery Risk Development in Young Adults. Ann Epidemiol 8:250\u2013261","journal-title":"Ann Epidemiol"},{"key":"489_CR35","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1001\/archinte.165.7.742","volume":"165","author":"Choi","year":"2005","unstructured":"Choi HK, Atkinson K, Karlson EW, Curhan G (2005) Obesity, weight change, hypertension, diuretic use and risk of gout in men: the health professionals follow-up study. Arch Intern Med 165:742\u2013748","journal-title":"Arch Intern Med"},{"key":"489_CR36","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/art.22466","volume":"57","author":"Choi","year":"2007","unstructured":"Choi HK, Ford ES, Li C, Curhan G (2007) Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 57:109\u2013115","journal-title":"Arthritis Rheum"},{"key":"489_CR37","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","volume":"289","author":"Chobanian","year":"2003","unstructured":"Chobanian AV, Bakris GL, Black HR et al (2003) The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the jnc 7 report. JAMA 289:2560\u20132572","journal-title":"JAMA"},{"key":"489_CR38","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/art.24612","volume":"61","author":"Kim","year":"2009","unstructured":"Kim SY, Guevara JP, Kim KM et al (2009) Hyperuricemia and risk of stroke: A systematic review and meta-analysis. Arthritis Rheum 61:885\u2013892","journal-title":"Arthritis Rheum"},{"key":"489_CR39","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1161\/STROKEAHA.108.519793","volume":"39","author":"Muir","year":"2008","unstructured":"Muir SW, Harrow C, Dawson J et al (2008) Allopurinol use yields potentially beneficial effects on inflammatory indices in those with recent ischemic stroke: a randomized, double-blind, placebo-controlled trial. Stroke 39:3303\u20133307","journal-title":"Stroke"},{"key":"489_CR40","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1086\/343053","volume":"71","author":"Williams","year":"2002","unstructured":"Williams CJ, Zhang Y, Timms A et al (2002) Autosomal dominant familial calcium pyrophosphate dihydrate deposition disease is caused by mutation in the transmembrane protein ANKH. Am J Hum Genet 71:985\u2013991","journal-title":"Am J Hum Genet"},{"key":"489_CR41","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00002281-200105000-00014","volume":"13","author":"Maldonado","year":"2001","unstructured":"Maldonado I, Reginato AM, Reginato AJ (2001) Familial calcium crystal diseases: what have we learned? Curr Opin Rheumatol 13:225\u2013233","journal-title":"Curr Opin Rheumatol"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-009-0489-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-009-0489-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-009-0489-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T12:35:59Z","timestamp":1559046959000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-009-0489-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,17]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["489"],"URL":"https:\/\/doi.org\/10.1007\/s00393-009-0489-4","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,17]]}}}